IP Library Granted Patent US 9,358,322
Granted Patent B2
US 9,358,322 · App. 13/891,052 · Granted Jun 7, 2016

Hyaluronic acid-based gels including lidocaine

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: ALLERGAN INDUSTRIE SAS
A61L27/20A61K8/42A61K8/735A61K31/167A61K31/728A61L27/52A61L27/54A61Q19/08A61L2300/402A61L2300/602
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,358,322
App. No.
13/891,052
Granted
Jun 7, 2016
Kind
B2
Abstract

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Claims (5)

1. A soft tissue filler composition comprising:

a sterile, stable injectable gel comprising a mixture of soluble form hyaluronic acid (HA), particles of HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and lidocaine in an amount effective to mitigate pain upon injection of the gel.

2. The soft tissue filler composition of claim 1 wherein the soluble form HA is present in an amount of about 10% to about 20% by volume.

3. The soft tissue filler composition of claim 1 wherein the HA of the particles has degree of crosslinking of less than about 6%.

4. The soft tissue filler composition of claim 1 wherein lidocaine is at a concentration of between about 0.1% and about 5% by weight of said composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2014
From: LEBRETON, PIERRE F.
To: ALLERGAN INDUSTRIE, S.A.S.
Reel/Frame 034567/0164 →
Continuity (5)
Continuation 12393768 · Feb 26, 2009
Provisional Application 61085956 · Aug 4, 2008
Provisional Application 61087934 · Aug 11, 2008
Provisional Application 61096278 · Sep 11, 2008
Related Publication 20130244970A1 · Sep 19, 2013